Posted on August 11, 2021 by Sitemaster
In 2016, we looked at the Candiolo risk stratification system for radiation therapy. To our knowledge, it has not been prospectively validated or widely adopted. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: nomogram. radiation, predictive, prognosis, risk, stratification, therapy | 4 Comments »
Posted on June 27, 2019 by Sitemaster
A newly published article in BJU International has described a way to test post-DRE urine samples for the presence of specific types of ribonucleic acid (RNA) and use these data to detect and classify risk levels for more and less aggressive forms of prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, prognosis, PUR, risk. classification, test, urine | 4 Comments »
Posted on May 7, 2019 by Sitemaster
The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk | Tagged: active, atenolol, biopsy, genomic, MRI, PI-RADS, predict, prognosis, scan, surveillance, test | 4 Comments »
Posted on April 27, 2019 by Sitemaster
Cochrane reviews are structured, systematic, focused reviews of evidence in the field of medicine that either support or do not support specific forms of diagnosis and management of patients with or suspected of having particular disorders. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: accuracy, biopsy, Diagnosis, fusion, MRI, MRi-guided, MRI/TRUS, prognosis, scan | 3 Comments »
Posted on March 13, 2019 by Sitemaster
A new paper just published in PLOS Medicine describes the development of a new online tool called PREDICT Prostate. … READ MORE …
Filed under: Uncategorized | Tagged: caclulator, nomogram, predict, predictor, prognosis, prostate, tool | 9 Comments »
Posted on February 27, 2019 by Sitemaster
A new “opinion” article in the Journal of Clinical Oncology this week has addressed the complex issue of how best to think about (a) how we are regulating use of and (b) how we are applying new forms of imaging technique in the management of prostate cancer … READ MORE …
Filed under: Uncategorized | Tagged: clinical, decision-making, Diagnosis, prognosis, scan | 4 Comments »
Posted on January 4, 2019 by Sitemaster
An obvious but previously unanswered question has been whether adding data from the results of MRI scans to the data used in the Partin tables and in the pre-surgical Kattan nomogram (also known as the Memorial-Sloan Kettering Cancer Center or MSKCC nomogram) can improve the accuracy of these two commonly used prognostic methods. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Kattan, MRI. mpMRI, MSKCC, multiparametric, nomogram, Partin, prognosis, risk, score | 3 Comments »
Posted on December 15, 2018 by Sitemaster
A newly published paper on the development of prostate cancer in patients of ≤ 55 years of age claims to have shown that
Using a newly-developed computer model, it is now possible to predict the course of the disease in individual patients. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genomics, medicine, modeling, personalized, prognosis | 2 Comments »
Posted on October 17, 2018 by Sitemaster
The “game changer” statement above comes from an independent review of the potential value of gallium-86-labeled prostate-specific molecular antigen (68Ga PSMA) PET scanning in the evaluation of selected men with prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management | Tagged: Diagnosis, gallium-68, PET, prognosis, PSMA, scan, work-up | 4 Comments »
Posted on July 5, 2018 by Sitemaster
An international, multi-institutional group of researchers appears to have been able to validate a new way to predict risk for aggressive forms of localized prostate cancer that have a high probability for progression to metastatic disease and prostate cancer-specific mortality. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "high risk", DNA, lethal, metastatic, methylation, prognosis, test | Leave a comment »
Posted on April 18, 2018 by Sitemaster
One of the critical and unanswered questions about the value of genomic/genetic testing in relation to the diagnosis and prognosis of prostate cancer is, “What are the currently available tests actually telling us compared to the clinical data?” … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Diagnosis, genetic, genomic, prognosis, risk, test | 2 Comments »
Posted on January 31, 2018 by Sitemaster
The concept of “minimal residual disease” or MRD and how it affects risk for cancer-specific mortality is a subject of growing importance in the management of many cancers. But it is relatively new to the world of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: disease, minimal, MRD, prognosis, residual | 3 Comments »
Posted on December 1, 2017 by Sitemaster
According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: cell, dagnosis, genomics, Gleason, grade, prognosis, score, single | 2 Comments »
Posted on November 19, 2017 by Sitemaster
Our friends at UroToday have just published a perfectly lovely lecture on this topic given by Prof. Lenny Gomella at the recent annual meeting of the Large Urology Group Practice Association (LUGPA). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, prognosis, screening, Treatment | 7 Comments »
Posted on October 24, 2017 by Sitemaster
A company based on Northern Ireland called Almac Diagnostics has been working on the development of a 70-gene genetic assay (which they refer to as their Prostate Cancer Metastatic Assay) capable of projecting probability of metastasis-free survival in men treated for prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: metastasis, prognosis, recurrence | 6 Comments »